Nuvation Bio Inc. (NYSE:NUVB – Get Free Report) shares hit a new 52-week low during mid-day trading on Thursday. The stock traded as low as $3.73 and last traded at $3.8850, with a volume of 564,977 shares changing hands. The stock had previously closed at $3.78.
Analyst Upgrades and Downgrades
Several brokerages have recently commented on NUVB. Royal Bank Of Canada reduced their price objective on shares of Nuvation Bio from $20.00 to $17.00 and set an “outperform” rating for the company in a research report on Thursday, November 5th. Citizens Jmp reiterated a “market outperform” rating and set a $10.00 target price on shares of Nuvation Bio in a research report on Wednesday, September 16th. Cantor Fitzgerald assumed coverage on shares of Nuvation Bio in a research report on Friday, August 21st. They set an “overweight” rating on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Nuvation Bio in a research note on Thursday, October 15th. Finally, JPMorgan Chase & Co. started coverage on shares of Nuvation Bio in a report on Tuesday, August 18th. They issued an “overweight” rating and a $13.00 price target for the company. Nine research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $13.00.
Check Out Our Latest Stock Analysis on Nuvation Bio
Nuvation Bio Price Performance
The company has a debt-to-equity ratio of 1.23, a quick ratio of 7.30 and a current ratio of 7.45. The business has a 50 day simple moving average of $4.87 and a 200-day simple moving average of $5.29. The firm has a market cap of $1.34 billion, a price-to-earnings ratio of -9.50 and a beta of 1.73.
Nuvation Bio (NYSE:NUVB – Get Free Report) last issued its quarterly earnings data on Wednesday, November 4th. The company reported ($0.12) earnings per share for the quarter, meeting the consensus estimate of ($0.12). The business had revenue of $44.95 million for the quarter, compared to analysts’ expectations of $34.39 million. Nuvation Bio had a negative return on equity of 45.69% and a negative net margin of 67.38%. Equities research analysts expect that Nuvation Bio Inc. will post -0.37 earnings per share for the current year.
Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of NUVB. American Century Companies Inc. grew its position in shares of Nuvation Bio by 0.4% during the 3rd quarter. American Century Companies Inc. now owns 4,519,041 shares of the company’s stock valued at $25,307,000 after acquiring an additional 19,398 shares during the period. Goldman Sachs Group Inc. increased its position in shares of Nuvation Bio by 136.9% during the third quarter. Goldman Sachs Group Inc. now owns 4,511,958 shares of the company’s stock valued at $25,267,000 after buying an additional 2,607,272 shares during the period. First Trust Advisors LP lifted its holdings in shares of Nuvation Bio by 19.7% in the third quarter. First Trust Advisors LP now owns 1,558,880 shares of the company’s stock worth $8,730,000 after buying an additional 256,543 shares in the last quarter. NewEdge Advisors LLC grew its position in shares of Nuvation Bio by 19.5% during the 2nd quarter. NewEdge Advisors LLC now owns 1,231,733 shares of the company’s stock valued at $6,996,000 after purchasing an additional 200,621 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership grew its holdings in shares of Nuvation Bio by 75.6% during the first quarter. Arrowstreet Capital Limited Partnership now owns 1,439,357 shares of the company’s stock worth $6,175,000 after purchasing an additional 619,725 shares in the last quarter. Institutional investors own 61.67% of the company’s stock.
About Nuvation Bio
Nuvation Bio is a biopharmaceutical company focused on developing and commercializing treatments for cancer. Founded in 2018 by physician and biotechnology executive David Hung, the company is headquartered in New York and is led by Hung as founder and chief executive officer. Its commercial product, Ibtrozi (taletrectinib), is an oral targeted therapy approved in the United States for adults with ROS1-positive non-small cell lung cancer. Nuvation Bio also develops investigational oncology medicines, including therapies targeting specific genetic changes and other features of cancer.
Further Reading
- Five stocks we like better than Nuvation Bio
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Nuvation Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvation Bio and related companies with MarketBeat.com's FREE daily email newsletter.
